Key Statistics for LGND
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (12/2013)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (USD)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for LGND
- Net Income (M/USD)
Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
More Company Profile & Key Executives for LGND
|John L HigginsPresident/CEO||Mathew W Foehr "Matt"Exec VP/COO|
|John P SharpVP:Finance/CFO||Charles S BerkmanVP/Secretary/General Counsel|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries